Clinical Efficacy of Ceftaroline Fosamil in Patients with Severe Pneumonia in Intensive Care Unit

Sánchez-Belmonte María José Pérez-Pedrero,Carretero Maria José Sánchez,Arevalo Marta Fernández,Casado Marcelino Sánchez,Pinilla Roman Hervey Piza

doi:10.23937/2474-3658/1510204

Sánchez-Belmonte María José Pérez-Pedrero, Carretero Maria José Sánchez + Show 3 more

Open Access

https://doi.org/10.23937/2474-3658/1510204

Copy DOI

Abstract

To evaluate our experience over the routine practice in the use of Ceftaroline fosamil (CF) as a treatment of severe community pneumonia in Intensive Care Unit (ICU) patients and to do a comparative with conventional antibiotics in terms of clinical efficacy.

Highlights

Severe community acquired pneumonia is entity with high mortality, it needs effective and early antibiotic therapy, and often the patients need admission in intensive care unit to receive respiratory support.Appearance of new antibiotics have been expanding the therapeutic efficacy, that approves of Ceftaroline fosamil to treat community acquired pneumonia have allowed to use it as a part of usual therapeutic arsenal and it have shown an earlier clinic response and higher cure rate.The goal of the study is to evaluate our experience with de use of Ceftaroline in patients with pneumonia and compare with conventional antibiotics in terms of clinical efficacy
We did a retrospective evaluation of critical patients that were admitted in Intensive Care Unit (ICU) in hospital Virgen de la Salud, in Toledo, Spain, with diagnosis of community acquired pneumonia (CAP) between January/2017 and December/2019, who were treated with antibiotics at least for 72 hours according to the choice of the physician in charge
Patients were classified in two cohorts: Citation: Belmonte MJPPS, Casado MS, Pinilla RHP, Arevalo MF, Carretero MJS (2021) Clinical Efficacy of Ceftaroline Fosamil in Patients with Severe Pneumonia in Intensive Care Unit

Summary

Introduction

Severe community acquired pneumonia is entity with high mortality, it needs effective and early antibiotic therapy, and often the patients need admission in intensive care unit to receive respiratory support.Appearance of new antibiotics have been expanding the therapeutic efficacy, that approves of Ceftaroline fosamil to treat community acquired pneumonia have allowed to use it as a part of usual therapeutic arsenal and it have shown an earlier clinic response and higher cure rate.The goal of the study is to evaluate our experience with de use of Ceftaroline in patients with pneumonia and compare with conventional antibiotics in terms of clinical efficacy. Severe community acquired pneumonia is entity with high mortality, it needs effective and early antibiotic therapy, and often the patients need admission in intensive care unit to receive respiratory support. Appearance of new antibiotics have been expanding the therapeutic efficacy, that approves of Ceftaroline fosamil to treat community acquired pneumonia have allowed to use it as a part of usual therapeutic arsenal and it have shown an earlier clinic response and higher cure rate. The goal of the study is to evaluate our experience with de use of Ceftaroline in patients with pneumonia and compare with conventional antibiotics in terms of clinical efficacy

Methods

Results

Conclusion